Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Seeing the future of bioactive lipid drug targets.

Evans JF, Hutchinson JH.

Nat Chem Biol. 2010 Jul;6(7):476-9. doi: 10.1038/nchembio.394. No abstract available.

PMID:
20559310
2.

Drugs targeting atherosclerosis: current and emerging approaches.

Manolopoulos VG, Tavridou A.

Curr Pharm Des. 2009;15(27):3091-3. No abstract available.

PMID:
19754383
3.

Artepillin C isoprenomics: design and synthesis of artepillin C analogues as antiatherogenic antioxidants.

Uto Y, Ae S, Hotta A, Terao J, Nagasawa H, Hori H.

Adv Exp Med Biol. 2006;578:113-8. No abstract available.

PMID:
16927679
4.

Omega-(2-Naphthyloxy) amino alkanes as a novel class of anti-hyperglycemic and lipid lowering agents.

Chaturvedi D, Ray S, Srivastava AK, Chander R.

Bioorg Med Chem. 2008 Mar 1;16(5):2489-98. Epub 2007 Nov 28.

PMID:
18083521
5.

Anti-atherosclerotic molecules targeting oxidative stress and inflammation.

Adameova A, Xu YJ, Duhamel TA, Tappia PS, Shan L, Dhalla NS.

Curr Pharm Des. 2009;15(27):3094-107. Review.

PMID:
19754384
6.

Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor alpha agonists.

Yamazaki Y, Abe K, Toma T, Nishikawa M, Ozawa H, Okuda A, Araki T, Oda S, Inoue K, Shibuya K, Staels B, Fruchart JC.

Bioorg Med Chem Lett. 2007 Aug 15;17(16):4689-93. Epub 2007 May 24.

PMID:
17553678
7.

Absolute stereochemistry of pentacecilides, new inhibitors of lipid droplet formation in mouse macrophages, produced by Penicillium cecidicola FKI-3765-1.

Yamazaki H, Ugaki N, Matsuda D, Tomoda H.

J Antibiot (Tokyo). 2010 Jun;63(6):315-8. doi: 10.1038/ja.2010.39. Epub 2010 Apr 23.

PMID:
20414320
8.

Molecule of the month.

Lindsley CW.

Curr Top Med Chem. 2008;8(12):1100. No abstract available.

PMID:
18693392
9.

Molecular pharmacophore determination of lipid lowering drugs with the receptor mapping method.

Ablise M, Cartier A, Siest G, Visvikis S, Loppinet V.

Mini Rev Med Chem. 2002 Apr;2(2):97-102.

PMID:
12370071
10.

Pentacecilides, new inhibitors of lipid droplet formation in mouse macrophages produced by Penicillium cecidicola FKI-3765-1: II. Structure elucidation.

Yamazaki H, Omura S, Tomoda H.

J Antibiot (Tokyo). 2009 Apr;62(4):207-11. doi: 10.1038/ja.2009.19. Epub 2009 Mar 20. Erratum in: J Antibiot (Tokyo). 2009 Nov;62(11):653-4.

PMID:
19300471
11.

Design, synthesis and hypolipidemic activity of novel 2-(m-tolyloxy) isobutyric acid derivatives.

Idrees GA, Abuo-Rahma Gel-D, Aly OM, Radwan MF.

Eur J Med Chem. 2009 Jun;44(6):2679-84. doi: 10.1016/j.ejmech.2008.12.009. Epub 2008 Dec 24.

PMID:
19121550
12.

Management of hyperlipidemias: an update.

Ranjan N.

Indian J Dermatol Venereol Leprol. 2009 Sep-Oct;75(5):452-62. doi: 10.4103/0378-6323.55387. Review.

13.

Fungal isobisvertinol, a new inhibitor of lipid droplet accumulation in mouse macrophages.

Koyama N, Ohshiro T, Tomoda H, Omura S.

Org Lett. 2007 Feb 1;9(3):425-8.

PMID:
17249778
14.

Novel euglycemic and hypolipidemic agents: Part-2. Antioxidant moiety as structural motif.

Reddy KA, Lohray BB, Bhushan V, Reddy AS, Kishore PH, Rao VV, Saibaba V, Bajji AC, Rajesh BM, Reddy KV, Chakrabarti R, Rajagopalan R.

Bioorg Med Chem Lett. 1998 May 5;8(9):999-1002. Erratum in: Bioorg Med Chem Lett 1998 Aug 4;8(15):2059.

PMID:
9871696
15.
16.

Design and synthesis of potent and subtype-selective PPARalpha agonists.

Desai RC, Metzger E, Santini C, Meinke PT, Heck JV, Berger JP, MacNaul KL, Cai TQ, Wright SD, Agrawal A, Moller DE, Sahoo SP.

Bioorg Med Chem Lett. 2006 Mar 15;16(6):1673-8. Epub 2005 Dec 27.

PMID:
16384704
17.

Evolutionary conservation of drug action on lipoprotein metabolism-related targets.

Hihi AK, Beauchamp MC, Branicky R, Desjardins A, Casanova I, Guimond MP, Carroll M, Ethier M, Kianicka I, McBride K, Hekimi S.

J Lipid Res. 2008 Jan;49(1):74-83. Epub 2007 Sep 27.

18.

Is Zetia a 'do nothing' drug?

Lindsley CW.

Curr Top Med Chem. 2008;8(5):434. No abstract available.

PMID:
18399020
19.

Emerging therapies targeting high-density lipoprotein metabolism and reverse cholesterol transport.

Duffy D, Rader DJ.

Circulation. 2006 Feb 28;113(8):1140-50. Review. No abstract available.

20.

(2R)-2-methylchromane-2-carboxylic acids: discovery of selective PPARalpha agonists as hypolipidemic agents.

Koyama H, Boueres JK, Miller DJ, Berger JP, MacNaul KL, Wang PR, Ippolito MC, Wright SD, Agrawal AK, Moller DE, Sahoo SP.

Bioorg Med Chem Lett. 2005 Jul 15;15(14):3347-51.

PMID:
15950464
Items per page

Supplemental Content

Write to the Help Desk